Search Results
531 results found-
Should you get both vaccinations? Yes, says an infectious disease doctor with the U.S. National Foundation for Infectious Diseases.
https://www.csl.com/we-are-csl/vita-original-stories/2021/protecting-yourself-from-covid-19-and-influenza -
CSL presents the World of Promise podcast series, focused on the promise of biotechnology.
https://www.csl.com/we-are-csl/csl-podcasts -
Since the COVID-19 pandemic, there has been a significant drop in influenza immunization rates and high levels of influenza-related illness, underscoring that flu is an ongoing threat.
https://newsroom.csl.com/2023-07-17-CSL-Seqirus-Begins-Shipping-Portfolio-of-Innovative-Influenza-Vaccines-for-the-2023-24-U-S-Season -
The agreement grants access to Arcturus Therapeutics' late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology, which recently reported results from a large COVID-19 Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favorable safety and tolerability profile.
https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics -
1 Additionally, enhanced vaccines are projected to further reduce the strain on hospitals and intensive care units by 10-15%, supporting bed availability during a potential COVID-19 endemic wave.
https://newsroom.csl.com/2023-09-18-CSL-Seqirus-Shares-Data-Demonstrating-the-Potential-for-Influenza-Vaccination-to-Reduce-the-Burden-on-Healthcare-Resources -
The COVID-19 pandemic and recently active flu season in the Southern Hemisphere attest to the burden high rates of respiratory infections, including influenza, can place on hospitals, which are the vanguard of a nation's health system," said Gregg Sylvester, MD, MPH, Chief Health Officer, CSL Seqirus.
https://newsroom.csl.com/2022-09-26-New-Data-at-OPTIONS-XI-Conference-Highlight-Burden-of-Seasonal-Influenza-on-Health-Systems-and-the-Need-for-Increased-Vaccination-Rates -
It has developed a COVID-19 vaccine candidate and has recently reported results from a large Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favorable safety and tolerability profile. "
https://newsroom.csl.com/2022-11-01-CSL-Enters-Licensing-Agreement-with-Arcturus-Therapeutics-for-Next-Generation-mRNA-Vaccine-Technology -
Circulation and Seasonality of Epidemics of Influenza, RSV and Other Respiratory Viruses Before, During, and After the COVID-19 Pandemic:
https://newsroom.csl.com/2023-09-15-CSL-Seqirus-to-Present-at-9th-ESWI-Conference-on-the-Burden-of-Influenza-and-Impact-of-Vaccination-on-Public-Health -
CSL's product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth.
https://www.csl.com/research-and-development/product-pipeline -
Primary immunodeficiency includes hundreds of disorders which affect the immune system, but with treatment, patients can lead full lives. Learn more about PID.
https://www.csl.com/patients-public-health/rare-and-serious-diseases/immunodeficiency-and-autoimmune-diseases/primary-immunodeficiency